Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00941785 | Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso | PHASE2 | COMPLETED | 1,500 | — | — | Jul 1, 2009 | Dec 1, 2009 | Mar 21, 2011 | 1 | Burkina Faso |
| Arm | Type | Description |
|---|---|---|
| DHA-PQ | EXPERIMENTAL | Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October. |
| SP-AQ | ACTIVE_COMPARATOR | Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine |
| Name | Type | Description |
|---|---|---|
| DHA-PQ | DRUG | Three monthly administrations of Duocotexcin (DHA-PQ): dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days |
| SP-AQ | DRUG | Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine: One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg |
Inclusion Criteria: * signed consent from a parent * age 3-59 months at enrolment * no history of allergy to study drugs * no chronic illness Exclusion Criteria: * history of allergy to study drugs * intention to move away from the study area before the end of 2009 * any chronic illness
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, Primaquine, Chloroquine, GSK3772701, RTS,S/AS01E vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |